USP and Public Policy

usp public policy
usp public policy

Refine Your Search

All Results
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024) Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024. Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024 Learn More
The USP submits comments to the Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“Guidance”) published by the Food and Drug Administration (… Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical… Learn More
USP Comment Letter submitted to Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment… Learn More
USP appreciates the opportunity to comment on the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q13 harmonized guideline draft. Learn More
USP appreciates this opportunity to submit comments on the proposed Safe Food for Canadians Regulations (the Proposed Regulations). Learn More